Drug news
Bardoxolone (Reata/Abbott) Phase III trial terminated for Chronic Kidney Disease
Reata Pharma, in consultation with the BEACON Steering Committee, has decided to terminate the Phase III BEACON trial of bardoxolone methyl in patients with stage 4 Chronic Kidney Disease and Type 2 Diabetes. This decision was made based upon a recommendation of the Independent Data Monitoring Committee (IDMC) to stop the trial "for safety concerns due to excess serious adverse events and mortality in the bardoxolone methyl arm". Abbott Labs have the ex US rights.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.